Efficacy of Lianhua Qingwen in Treating Patients Infected With the Omicron Variant of the COVID-19
NCT ID: NCT05778318
Last Updated: 2023-05-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2023-03-20
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lianhua Qingke for the Rehabilitation of Patient With Omicron Infection
NCT05625022
Efficacy of TCM Capsules Lian Hua Qing Wen Jiao Nang in Mild COVID-19 Patients
NCT05275933
A Randomized Controlled Trial Assessing the Efficacy of Lianhua Qingwen as an Adjuvant Treatment in Patients With Mild Symptoms of COVID-19
NCT04433013
Lianhua Qingwen for the Rehabilitation of Patient With Coronavirus Infection
NCT05625035
Effect of a Traditional Chinese Medicine Formulation on COVID-19 Infection
NCT05672498
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control group
Patients without Lianhua Qingwen treatment.
The group of patients who did not receive Lianhua Qingwen orally
The group of patients who did not receive Lianhua Qingwen orally.
Observation Group
Patients with Lianhua Qingwen treatment.
The group of patients who received Lianhua Qingwen orally
Lianhua Qingwen Granules: oral. One bag at a time, three times a day. The course of treatment for mild and ordinary cases of novel coronavirus pneumonia is 7-10 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
The group of patients who received Lianhua Qingwen orally
Lianhua Qingwen Granules: oral. One bag at a time, three times a day. The course of treatment for mild and ordinary cases of novel coronavirus pneumonia is 7-10 days.
The group of patients who did not receive Lianhua Qingwen orally
The group of patients who did not receive Lianhua Qingwen orally.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The clinical symptoms were classified as mild or ordinary.
* They have been vaccinated against the COVID-19.
Exclusion Criteria
* Severe and critical patients with COVID-19.
* Patients with chronic respiratory diseases, bacterial infections of the respiratory system, and other respiratory diseases affecting the study.
* Patients with serious primary diseases of the heart, brain, lung, liver, kidney, and hematopoietic systems, as well as mental diseases.
* Allergic reaction to Lianhua Qingwen granules.
* Excluded patients treated with the same drug as Lianhua Qingwen.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Qianfoshan Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Qian Qi
Dr.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Respiratory, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, #16766, Jingshi Road, Jinan City, Shandong Province, China
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YXLL-KY-2022(095)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.